4.3 Review

Systemic lupus erythematosus and cardiovascular disease: prediction and potential for therapeutic intervention

Journal

EXPERT REVIEW OF CLINICAL IMMUNOLOGY
Volume 7, Issue 2, Pages 227-241

Publisher

TAYLOR & FRANCIS LTD
DOI: 10.1586/ECI.10.98

Keywords

apoA-1; atherosclerosis; HMG-CoA reductase inhibitors; homocysteine; oxidized LDL; proinflammatory HDL; statins; systemic lupus erythematosus

Categories

Funding

  1. Arthritis Foundation
  2. NIH/NIAMS [1K23AR053864-01A1]
  3. Rheuminations

Ask authors/readers for more resources

Patients with systemic lupus erythematosus have a significantly increased risk of cardiovascular events due to atherosclerosis. Traditional cardiac risk factors cannot fully explain this increased risk. Recent evidence strongly suggests that atherosclerotic plaque is largely driven by inflammation and an active immunological response, in contrast to the long-held belief that plaque is a passive accumulation of lipids in the arterial wall. Current approaches to the prevention of atherosclerosis in systemic lupus erythematosus involve targeting modifiable cardiac risk factors. Future preventive strategies may include therapies that counteract the immunologic responses that lead to plaque formation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available